What do systematic reviews say?

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 167 participants
  Very low

G‐CSF vs placebo

The review found no eligible studies for this question.

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Very low

GM-CSF vs placebo

GM‐CSF showed no clear difference in mortality (12 months compared with placebo (low certainty).

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  HR 0.88 [0.62, 1.26]
  2 studies · 149 participants
  Low

GM-CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 149 participants
  Low

Intervention not reported

The intervention may leads to higher the rate of improvement in CT images ( (low certainty).

• Macrolides for diffuse panbronchiolitis 2015 · Cochrane Headline outcomes only
  RR 15.38 [1.05, 225.73]
  1 study · 19 participants
  Low

Intervention not reported

The intervention may leads to lower the rate of progress in CT images ( (low certainty).

• Macrolides for diffuse panbronchiolitis 2015 · Cochrane Headline outcomes only
  RR 0.06 [0, 0.88]
  1 study · 19 participants
  Low